{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T17:10:28Z","timestamp":1716052228802},"reference-count":58,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T00:00:00Z","timestamp":1380067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":706,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>To further define the relative impact of immunotherapy and subsequent development of graft\u2010versus\u2010host disease (<jats:styled-content style=\"fixed-case\">GVHD<\/jats:styled-content>) on survival in patients with relapsed acute leukaemia postallogeneic hematopoietic stem cell transplant (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>), we performed a single\u2010centre retrospective analysis of 32 actively treated patients between 2003 and 2011.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 13 patients were identified who were treated actively with cessation of immunosuppression \u00b1 Fludarabine, Cytarabine, G\u2010CSF (<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>) induction, but no donor leucocyte infusion (<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>) (non\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>group) and 19 patients received the same step\u2010wise therapy plus G\u2010<jats:styled-content style=\"fixed-case\">CSF<\/jats:styled-content>mobilized<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>(G\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Groups were not statistically different with regards to baseline characteristics; however, the G\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>group contained more sibling donors as opposed to unrelated donors than the non\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>group. With a median follow\u2010up of 47\u00a0months, the median overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) of the non\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>and G\u2010<jats:styled-content style=\"fixed-case\">DLI<\/jats:styled-content>groups was not statistically different (8\u00a0months<jats:italic>vs<\/jats:italic>. 9\u00a0months, respectively,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.5). Survival at 3\u00a0years was &lt;10% in both groups. Univariate analysis identified response to<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>, and new onset chronic<jats:styled-content style=\"fixed-case\">GVHD<\/jats:styled-content>as the only factors associated with improved<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Second donor stem cell infusions are unwarranted in the treatment of relapse after allogeneic<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>and therapeutic strategies should focus on cytoreduction followed by immune modulation with the aim of invoking chronic<jats:styled-content style=\"fixed-case\">GVHD<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.12153","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T21:53:10Z","timestamp":1381528390000},"page":"197-204","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy following relapse of acute leukaemia after T\u2010cell\u2010replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft\u2010versus\u2010host disease"],"prefix":"10.1111","volume":"36","author":[{"given":"C.","family":"Curley","sequence":"first","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Royal Brisbane and Women's Hospital Brisbane Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Royal Brisbane and Women's Hospital Brisbane Qld Australia"},{"name":"Queensland Institute of Medical Research Brisbane Qld Australia"},{"name":"University of Queensland Brisbane Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Royal Brisbane and Women's Hospital Brisbane Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.A.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Royal Brisbane and Women's Hospital Brisbane Qld Australia"},{"name":"University of Queensland Brisbane Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.001"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.09.005"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.50"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704645"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.06.007"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403523"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.2.405"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.671"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504242921706"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12058."},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00013.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700934"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00142-9"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700720"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700859"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058408"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705024"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702555"},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic progenitor cells with purine analog\u2010containing chemotherapy: harnessing graft\u2010versus_leukemia without myeloablative therapy","volume":"89","author":"Giralt S","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4299"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.144"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03150.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702101"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400585"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.08.003"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402048"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01851.x"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704761"},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V92.2.394","article-title":"Association between pretransplant interferon \u2013 a and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase","volume":"92","author":"Morton AJ","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_35_1","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood.V94.11.3668","article-title":"Interferon\u2010a before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90\u00a0days before the procedure","volume":"94","author":"Hehlmann R","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300204"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.11.003"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-6-809"},{"key":"e_1_2_5_39_1","first-page":"115","article-title":"Interferon\u2010alpha and interleukin\u20102 as treatment for leukemia relapse after allogeneic bone marrow transplantation","volume":"1","author":"Giralt S","year":"1995","journal-title":"Cytokines Mol Ther"},{"key":"e_1_2_5_40_1","first-page":"317","article-title":"Treatment of leukemia relapse after bone marrow transplantation with interferon\u2010alpha and interleukin 2","volume":"15","author":"Shaffer L","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21346"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.12.050"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08889.x"},{"key":"e_1_2_5_44_1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.12065","article-title":"Treatment of relapsed myelodysplastic syndrome following double umbilical cord blood transplantation with interferon alpha and 5\u2010azacytidine","volume":"159","author":"Samuelson C","year":"2012","journal-title":"Br J Haematol"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-368076"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001302"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700680"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3675"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404828"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.300"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.414"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705011"},{"key":"e_1_2_5_55_1","first-page":"269","article-title":"Second HLA\u2010identical sibling transplants for leukemia recurrence","volume":"9","author":"Mrsic M","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.304"},{"key":"e_1_2_5_57_1","first-page":"331","article-title":"Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long\u2010term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON)","volume":"87","author":"Munoz A","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.255"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijlh.12153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.12153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T16:35:17Z","timestamp":1716050117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.12153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,25]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/ijlh.12153"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.12153","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,25]]},"assertion":[{"value":"2013-09-25","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}